PharmaShots | Incisive News in 3 Shots

Subscribe Now

metastatic uveal melanoma

Immunocore's Tebentafusp Receives the US FDA's Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma

Immunocore's Tebentafusp Receives the US FDA's Breakthrough Therapy Designation for Unresectable or Metastatic Uveal Melanoma

February 22, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us